Cleveland BioLabs Loses Out to Osiris For Radiation Treatment Contract
As we reported earlier today, Osiris Therapeutics won a Department of Defense contract to develop a treatment for radiation sickness. Unfortunately, Osiris’s gain was Cleveland BioLabs’ loss. Cleveland’s “shares plummeted nearly 60% after the Buffalo, N.Y., company’s proposed treatment for the gastrointestinal effects of radiation sickness, Protectan CBLB502, wasn’t chosen.” More details at The Street.
Tagged with: Buffalo, Prochymal, Protectan CBLB502
